Overall, while sTREM2 reflects ongoing microglial activation and appears mechanistically relevant to MS pathology, its prognostic and diagnostic utility remains less definitive compared to CHIT1, necessitating further large-scale longitudinal validation. The gene discussed is CHIT1; the disease is myeloid sarcoma.